Edgewise Therapeutics, Inc. Shareholders' Equity
Edgewise Therapeutics, Inc. (EWTX) had Shareholders' Equity of $448.08 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $448.08M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $493.20M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $522.26M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $558.65M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $448.08M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $493.20M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $522.26M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $558.65M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $589.07M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $429.72M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $459.22M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $488.88M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $510.47M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $534.94M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $318.83M 10-K · filed 2026-02-26 |
| 2023-09-30 | $290.43M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $311.45M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $328.84M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $346.72M 10-K · filed 2026-02-26 |
| 2022-09-30 | $361.40M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $246.35M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $260.36M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $274.38M 10-K · filed 2024-02-22 |
| 2021-09-30 | $285.40M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $296.75M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $306.39M 10-Q · filed 2022-11-03 |
| 2020-12-31 | -$33.42M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$27.27M 10-Q · filed 2021-11-10 |
| 2020-06-30 | -$23.76M 10-Q · filed 2021-11-10 |
| 2020-03-31 | -$19.98M 10-Q · filed 2021-11-10 |
| 2019-12-31 | -$16.85M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |